

Edgar Filing: ABIOMED INC - Form 8-K

ABIOMED INC
Form 8-K
May 30, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: May 23, 2008

(Date of earliest event reported)

ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction
of Incorporation)

04-2743260
(IRS Employer
Identification Number)

0-20584
(Commission File Number)

22 Cherry Hill Drive
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400
(Registrant's Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ABIOMED INC - Form 8-K

=====
 Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
 Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On May 23, 2008, our compensation committee made its annual compensation determinations for our executive officers. The committee determined the bonuses for fiscal 2008 performance, the salaries for fiscal 2009 and made the annual equity grants to executive officers. The compensation decisions made with respect to our executive officers who were named executive officers in our most recent proxy statement were as follows:

Executive Officer	Fiscal 2008 Bonus	Fiscal 2009 Salary	Shares Underlying Stock Options (4 year vesting)	(4
Michael R. Minogue, Chairman, CEO and President	\$354,000	\$371,700	43,333	
Daniel J. Sutherby, Chief Financial Officer	\$75,000	\$236,385	10,000	
Andrew J. Greenfield, Vice President Healthcare Solutions	\$75,000	\$194,555	9,000	

=====
 SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Abiomed, Inc.

By: /s/ Daniel J. Sutherby

 Daniel J. Sutherby
 Chief Financial Officer

Date: May 30, 2008